PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy could help control advanced gastroesophageal cancer that cannot be surgically removed. Sixteen participants received the combination to see if it could shrink or elimin…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:04 UTC
-
New cocktail of immune drugs and radiation shows promise against stomach cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation before surgery can help treat stomach cancer that is still removable. About 32 adults with early-stage stomach or gastroesophageal junction cancer will receive…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
New way to deliver chemotherapy shows promise for stomach cancer patients
Disease control OngoingThis early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study includes 27 pa…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC